Topotecan and doxorubicin combination to treat recurrent ovarian cancer: The influence of drug exposure time and delivery systems to achieve optimum therapeutic activity

Clinical Cancer Research

Volumn 19, Issue 4, 2013, Pages 865-877

  Patankar, Nilesh A ^a,c,e   Pritchard, Julia ^c   Van Grinsven, Mariska ^c   Osooly, Maryam ^e   Bally, Marcel B ^a,b,c,d  

^a Faculty of Pharmaceutical Sciences   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Centre for Drug Research and Development   (Canada)

^e MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TOPOTECAN; TREATMENT OUTCOME;

EID: 84874058291     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2459     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.AmJ Surg Pathol 2010;34:433-43.
3. Ahmad T, Gore M. Review of the use of topotecan in ovarian carcinoma. Expert Opin Pharmacother 2004;5:2333-40.
4. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86.
5. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2005;2:341-51.
6. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets 2006;6:455-89.
7. Chou T. Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press; 1991.
8. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
9. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
10. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42.
11. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001;37:69-82.
12. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
14. Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 2004;94:67-73.
15. Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 2000;10:33-7.
16. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6.
17. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
18. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989;989:163-77.
19. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin- DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006;66:4863-71.
20. Dupont J, Aghajanian C, Andrea G, Lovegren M, Chuai S, Venkatraman E, et al. Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? Int J Gynecol Cancer 2006;16 Suppl 1:68-73.
21. Ghesquieres H, Faivre S, Djafari L, Pautier P, Lhommé C, Lozahic S, et al. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. Invest New Drugs 2006;24:413-21.
22. Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998;54: 509-14.
23. Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2006;10:1-132, iii-iv.
24. Harasym TO, Tardi PG, Johnstone SA, Mayer LD, Bally MB, Janoff AS. Fixed drug ratio liposome formulations of combination cancer therapeutics. In: Liposome technology. 3rd ed. New York, NY: Informa Healthcare; 2006. p. 25-48.
25. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-63.
26. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129-39.
27. Dadashzadeh S, Vali AM, Rezaie M. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm 2008;353:251-9.
28. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2010;141: 13-21.
29. Liu JJ, Hong RL, Cheng WF, Hong K, Chang FH, Tseng YL. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 2002;13:709-17.
30. Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. Topophore C™: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Invest New Drugs. 2012 May [Epub ahead of print].
31. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1990;1023:133-9.
32. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
33. Waterhouse DN, Kalra J. Nanotechnology as an enabling approach to the development of fixed-dose combination products for treating cancer. Valencia (CA): American Scientific Publishers; 2008.
34. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
35. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 1994;34: 137-46.
36. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007;105:404-8.
37. Pather S, Quinn MA. Clear-cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer 2005;15:432-7.
38. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 2006;11:1089-94.
39. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
40. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-7.
41. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
42. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
43. Carter WH Jr, Wampler GL. Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treat Rep 1986;70:133-40.
44. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58.
45. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
46. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
47. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, et al. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 1988;47:97-107.
48. Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998;127:99-106.
49. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696-740.